Company Description
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products.
It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands.
The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies.
The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013.
Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1887 |
| IPO Date | Dec 16, 1991 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8,100 |
| CEO | Patrick Lockwood-Taylor |
Contact Details
Address: The Sharp Building, Hogan Place Dublin, D02 TY74 Ireland | |
| Phone | 353 1 709 4000 |
| Website | perrigo.com |
Stock Details
| Ticker Symbol | PRGO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001585364 |
| CUSIP Number | G97822103 |
| ISIN Number | IE00BGH1M568 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Patrick Lockwood-Taylor | President, Chief Executive Officer and Director |
| Eduardo Guarita Bezerra | Executive Vice President and Chief Financial Officer |
| Ronald C. Janish | Chief Transformation Officer |
| Roberto Khoury | Executive Vice President and Chief Commercial Officer |
| Abbie Lennox | Executive Vice President and Chief Scientific Officer |
| Bradley Joseph | Vice President of Global Investor Relations and Corporate Communications |
| Charles Atkinson | Executive Vice President, General Counsel and Secretary |
| Robert Willis | Chief Human Resources Officer and Executive Vice President |
| Dr. David Ball | Executive Vice President and Chief Brand and Digital Officer |
| Matthew Winterman | Executive Vice President of Product Supply, Operations Strategy and Transformation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2026 | ARS | Filing |
| Mar 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 20, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 5, 2026 | SCHEDULE 13G | Filing |
| Jan 8, 2026 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 5, 2025 | 10-Q | Quarterly Report |